Diamonds and Dogs

1/11/22

Illumina (ILMN) shines brightly. Biotech Illumina is up 13% after raising guidance at JP Morgan Healthcare conference. Demand has expanded for Illumina's test to help doctors choose the best treatment for a cancer. States are also helping pay or reimburse Illumina's tests for genetic diseases for children under the Medicaid program. The Covid-19 pandemic is jolting global groups to budget $165 billion in the next decade for global surveillance of new infectious organisms using tests like Illuminas.

Two steps forward, two steps back. After a nice run up to start the year, IBM (IBM) is down 2% on a downgrade to sell over at UBS. The analyst believes investors are getting too optimistic about earnings growth in the short term and the stock may be ahead of the fundamentals. Here we go again.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.